The efficacy and safety of nivolumab in previously treated advanced non-small-cell lung cancer: a meta-analysis of prospective clinical trials

Jiaxing Huang1,2,*
Yaxiong Zhang1,2,*
Jin Sheng1,2,*
Hongyu Zhang3
Wenfeng Fang1,2
Jianhua Zhan1,2
Ting Zhou1,2
Ying Chen1,2
Lin Liu1,2
Li Zhang1,2

1Department of Medical Oncology, Sun Yat-Sen University Cancer Center, 2State Key Laboratory of Oncology in South China, 3Department of Medical Oncology, the Fifth Affiliated Hospital of Sun Yat-Sen University, Zhuhai, Guangdong, People’s Republic of China

*These authors contributed equally to this work

Introduction
Lung cancer is one of the most common malignancies and the leading cause of cancer-related deaths around the world.1 Approximately 85% of patients have non-small-cell lung cancer (NSCLC), and about 80% cases were diagnosed at an advanced stage.2,3 Moreover, the prognosis and overall survival (OS) rate of patients with...
advanced NSCLC are very low.\textsuperscript{4} Surgery, chemotherapy, and radiotherapy were the three primary treatment modalities for NSCLC in the past. In the past decade, targeted therapies, such as epidermal growth factor receptor and anaplastic lymphoma receptor tyrosine kinase inhibitors, have helped control tumor growth effectively for patients harboring specific genetic abnormalities. However, a large proportion of patients have limited benefits due to lack of driver mutation, especially for patients with advanced squamous NSCLC.\textsuperscript{5–8} Nevertheless, for patients whose disease worsens after initial treatment, the second-line docetaxel regimen offers modest benefit. What is more, the AEs of docetaxel regimen are always hard to bear.\textsuperscript{9,10}

In these special cases, immune checkpoint inhibition therapy serves as a new therapeutic approach for patients with previously advanced treated NSCLC, which takes effect by restoring the immune system’s capacity to recognize and eradicate tumors.\textsuperscript{11} The programmed death (PD)-1 receptor expressed on activated T-cells is engaged by the tumor-expressed ligands PD-L1 (B7-H1) and PD-L2 (B7-H1) to downregulate T-cell activation and promote tumor cells to escape recognition and elimination by the immune system.\textsuperscript{12} Nivolumab (BMS-936558) is a fully human IgG4 PD-1 immune-checkpoint-antibody that disrupts T-cell activation and proliferation and restores antitumor immunity.\textsuperscript{13–16} Recently, a Phase III randomized clinical trial (Checkmate017)\textsuperscript{17} of nivolumab for patients with previously treated advanced squamous NSCLC demonstrated that compared to standard second-line docetaxel regimen, nivolumab significantly gained the better median OS (9 months versus 6 months), nearly doubling the 1-year survival rate (42\% versus 24\%). In addition, another Phase III randomized clinical trial (Checkmate057)\textsuperscript{18} for patients with non-squamous NSCLC worsened after platinum-based doublet chemotherapy revealed that compared to standard chemotherapy, nivolumab significantly prolonged the median survival (12.2 months versus 9.4 months).\textsuperscript{17–19} Hence, nivolumab was approved by US Food and Drug Administration for the treatment of squamous as well as non-squamous lung cancer that progressed after platinum-based doublet chemotherapy.\textsuperscript{19} However, these two trials cannot characterize subgroups of patients whose disease progresses early and who may benefit most from nivolumab, and more reliable data of safety of nivolumab are warranted. Beyond that, there have been several trials assessing the efficacy of previously treated advanced NSCLC with nivolumab.\textsuperscript{13,20–25} Moreover, in view of the limitation that different doses within the different phase clinical trials which could display the various efficacy, it is important and necessary to conduct a timely summarization at the same efficacious dose of 3 mg/kg. Recently, several studies demonstrated that the dose (3 mg/kg) was a preferential dosage of nivolumab.\textsuperscript{13,20} Thus, we performed this meta-analysis systematically combining data from published clinical trials to evaluate the efficacy and safety of nivolumab at the efficacious dose of 3 mg/kg in previously treated advanced NSCLC.

Materials and methods

Literature search

The relevant data were rigorous searched to identify clinical trials from Embase, PubMed (MEDLINE), and Cochrane Library, from January 2007 to March 2016. Correlated meeting abstracts were also retrieved at the American Society of Clinical Oncology, the European Society for Medical Oncology, and the World Conference of Lung Cancer. The search strategy used both MeSH terms and free-text words to increase sensitivity. A combination of terms was used: “Nivolumab/ONO-4538/BMS-936,558/MDX-1106/Opdivo” and “lung cancer/carcinoma”.

Inclusion and exclusion criteria

Eligible studies were required to meet the following criteria: 1) articles with prospective trials investigating nivolumab on advanced NSCLC patients; 2) studies reporting any of the following information: objective response rate, disease control rate (DCR), OS, progression-free survival (PFS), and grade 3–4 AEs. Exclusion criteria were the following: 1) duplicate publications; 2) studies without usable data; and 3) letters, editorials, case reports, and reviews.

Data extraction and quality control

Our primary outcome was ORR, secondary outcomes PFS, OS, DCR, and toxicity profile with the efficacy dose of 3 mg/kg. Two investigators performed the search independently to avoid bias in the data-extraction process. Disagreement over eligibility of a study was resolved by consensus or by the third investigator. For each study, we extracted the key information: name of the first author, year of publication, trial phase, number of participants, dose, PD-L1 expression level (PD-L1 positive: PD-L1 expression ≥ 5\%, PD-L1 negative: PD-L1 expression < 5\%), tumor cell histology as well as the outcomes mentioned above. The data collection and assessment of methodological quality followed the Cochrane Collaboration guidelines (http://www.cochrane.de). In addition, a Newcastle–Ottawa scale was used by three reviewers (J Huang, Y Zhang, and J Sheng) to estimate all the
prospective and retrospective studies. Discrepancies were discussed by all investigators to reach a consensus.26

Statistical analysis
Odds ratios for dichotomous data (ORR) with 95% confidence interval (CI) were pooled. Heterogeneity across studies was assessed with a forest plot and the inconsistency statistic ($I^2$). A random-effects model was employed in case of the existence of potential heterogeneity ($I^2>50\%$), otherwise, fixed-effect models were used. All calculations were performed using Review Manager 5.3 (Nordic Cochrane Centre, Copenhagen, Denmark) and R software (version 3.2.2). $P<0.05$ was considered statistically significant for all analyses.

Publication bias
An extensive search strategy was made to minimize the potential for publication bias. Graphical funnel plots were generated to visually assess a publication bias. Begger’s test and Egger’s funnel plots were performed to assess the funnel plot asymmetry.27,28

Results
Study selection and characteristics
Overall, a total of 421 records were identified according to the search strategy; 330 records were excluded after screening the titles and abstracts. Fifty-one studies were excluded after reviewing each publication. As for the remaining 13 potentially relevant studies, four studies were excluded due to being without primary outcomes, and finally we enrolled nine studies involving 892 NSCLC patients.13,17,18,20–25 Figure 1 shows the studies selection process, and the flow chart of the nine selected clinical trials. Table 1 summarizes the characteristics of the included studies and agents.

Efficacy
Meta-analysis of nivolumab in terms of ORR, DCR, 1-year-OS rate, and 1-year-PFS rate
In summary, at the dose of 3 mg/kg, all trials presented the information on ORR. As shown in Figure 2A, the pooled ORR of the whole population of nivolumab was 20% (95% CI: 17%–23%) without heterogeneity ($I^2=0\%$, $P=0.562$). Only four trials presented the information about DCR, the pooled rate was 36% (95% CI: 22%–51%) with significant heterogeneity ($I^2=92.4\%$, $P<0.0001$), which is presented in Figure 2B. In addition, for the survival benefit, the pooled 1-year-OS rate was 47% (95% CI: 40%–53%) with median heterogeneity ($I^2=51.3\%$, $P=0.103$; Figure 2C), while the pooled 1-year-PFS rate was 21% (95% CI: 18%–24%) with small heterogeneity ($I^2=0\%$, $P=0.519$; Figure 2D).

Toxicity
In general, nine studies provided data on grade 3–4 nivolumab-related AEs, while five studies presented the data on any grade AEs. The pooled rate of any grade AEs is 63% (95% CI: 51%–72%), while the pooled rate of grade 3–4 AEs is only 8% (95% CI: 6%–12%) with significant heterogeneity ($I^2=75.5\%$, $P<0.0001$) (Figure 3A and B). Rates of any grade of common AEs of nivolumab were analyzed, and included fatigue (28%, 95% CI: 24%–33%), decreased appetite (13%, 95% CI: 9%–17%), nausea (12%, 95% CI: 9%–16%), asthenia (10%, 95% CI: 8%–13%), diarrhea (8%, 95% CI: 6%–11%), pneumonitis (4%, 95% CI: 2%–6%), rash (4%, 95% CI: 2%–6%), anemia (3%, 95% CI: 1%–3%), and myalgia (3%, 95% CI: 2%–5%). However, all common AEs of grade 3–4 were 10%. More details are presented in Table 2.

Subgroup analysis
Non-squamous versus squamous cell lung cancer
As for the different histology types NSCLC, within the efficacy dose of 3 mg/kg. The pooled ORR of squamous cell lung cancer was 20% (95% CI: 16%–25%) with small heterogeneity ($I^2=14.6\%$, $P=0.320$), while the pooled ORR of non-squamous cell lung cancer was 20% (95% CI: 17%–24%) with small heterogeneity ($I^2=0\%$, $P=0.888$). Additionally, for
Table 1 Characteristics of included studies and agents

<table>
<thead>
<tr>
<th>Author and year</th>
<th>Phase Study arms</th>
<th>Number of patients</th>
<th>Tumor cell histology</th>
<th>Median PFS (month)</th>
<th>Median OS (month)</th>
<th>1-year survival rate (%)</th>
<th>ORR</th>
<th>DCR</th>
<th>≥ grade 3 AEs (%)</th>
<th>1-year-PFS rate</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brahmer et al 2015 (CheckMate017)</td>
<td>III Nivolumab 3 mg/kg</td>
<td>135</td>
<td>100% squamous</td>
<td>3.5</td>
<td>9.2</td>
<td>42 (57/135)</td>
<td>20 (27/135)</td>
<td>49 (66/135)</td>
<td>7 (9/135)</td>
<td>21 (29/135)</td>
</tr>
<tr>
<td></td>
<td>Docetaxel</td>
<td>137</td>
<td>2.8</td>
<td>6.0</td>
<td>24 (33/137)</td>
<td>9 (12/137)</td>
<td>43 (59/137)</td>
<td>55 (71/129)</td>
<td>6 (9/137)</td>
<td></td>
</tr>
<tr>
<td>Gettinger et al 2015 and Brahmer 2014 (ASCO abstract)</td>
<td>I Nivolumab 1 mg/kg</td>
<td>33</td>
<td>41.9% squamous</td>
<td>2.3</td>
<td>9.2</td>
<td>33 (113/33)</td>
<td>3 (1/33)</td>
<td>NA</td>
<td>5/33</td>
<td>19 (6/33)</td>
</tr>
<tr>
<td></td>
<td>Nivolumab 3 mg/kg</td>
<td>37</td>
<td>14.9</td>
<td>56 (21/37)</td>
<td>24 (9/37)</td>
<td>NA</td>
<td>5/37</td>
<td>30 (11/37)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Nivolumab 10 mg/kg</td>
<td>59</td>
<td>9.2</td>
<td>38 (23/59)</td>
<td>20 (12/59)</td>
<td>NA</td>
<td>8/59</td>
<td>19 (11/59)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Borghaei et al 2015 (CheckMate057)</td>
<td>III Nivolumab 3 mg/kg</td>
<td>292</td>
<td>100% non-squamous</td>
<td>2.3</td>
<td>12.2</td>
<td>51 (149/292)</td>
<td>19 (56/292)</td>
<td>49 (130/292)</td>
<td>10 (30/287)</td>
<td>19 (56/292)</td>
</tr>
<tr>
<td></td>
<td>Docetaxel</td>
<td>290</td>
<td>4.2</td>
<td>9.4</td>
<td>39 (114/290)</td>
<td>12 (36/290)</td>
<td>59 (158/290)</td>
<td>54 (144/268)</td>
<td>8 (24/290)</td>
<td></td>
</tr>
<tr>
<td>Rzvi et al 2015 (CheckMate063)</td>
<td>II Nivolumab 3 mg/kg</td>
<td>117</td>
<td>100% squamous</td>
<td>1.9</td>
<td>8.2</td>
<td>41 (48/117)</td>
<td>15 (17/117)</td>
<td>26 (47/117)</td>
<td>17 (20/117)</td>
<td>20 (24/117)</td>
</tr>
<tr>
<td>Nishio 2015 (ASCO abstract)</td>
<td>II Nivolumab 111</td>
<td>35/111 squamous</td>
<td>4.3</td>
<td>NR</td>
<td>NR</td>
<td>26 (9/35)</td>
<td>NR</td>
<td>16 (18/111)</td>
<td>NR</td>
<td></td>
</tr>
<tr>
<td></td>
<td>76/111 non-squamous</td>
<td>2.8</td>
<td>NR</td>
<td>NR</td>
<td>20 (15/76)</td>
<td>NR</td>
<td>NR</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>13/19 non-squamous</td>
<td>NR</td>
<td>NA</td>
<td>NA</td>
<td>23 (3/13)</td>
<td>NA</td>
<td>NR</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Brahmer 2012 (ASCO abstract)</td>
<td>I Nivolumab 19</td>
<td>17/75 squamous</td>
<td>NA</td>
<td>NA</td>
<td>28 (5/18)</td>
<td>NA</td>
<td>8 (20/240)</td>
<td>NA</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>52/75 non-squamous</td>
<td>6/75 unknown type</td>
<td>NA</td>
<td>NA</td>
<td>28 (5/18)</td>
<td>NA</td>
<td>8 (20/240)</td>
<td>NA</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Brahmer et al 2013 (WCLC abstract)</td>
<td>I Nivolumab 3 mg/kg</td>
<td>37</td>
<td>18/37 squamous</td>
<td>NA</td>
<td>9.5</td>
<td>NA</td>
<td>22 (4/18)</td>
<td>NA</td>
<td>5 (6/129)</td>
<td>NA</td>
</tr>
<tr>
<td></td>
<td>19/37 non-squamous</td>
<td>18.2</td>
<td>NA</td>
<td>NA</td>
<td>26 (5/19)</td>
<td>NA</td>
<td>5 (6/129)</td>
<td>NA</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Todd 2015 (ASCO abstract, CheckMate153)</td>
<td>IIIb/IV Nivolumab 226</td>
<td>26% squamous</td>
<td>NA</td>
<td>NA</td>
<td>13 (7/51)</td>
<td>57 (29/51)</td>
<td>1.8 (4/226)</td>
<td>NA</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Abbreviations: ASCO, American Society of Clinical Oncology; DCR, disease control rate; NA, not applicable; NR, not reachable; ORR, objective response rate; OS, overall survival; PFS, progression-free survival; WCLC, World Conference of Lung Cancer; AEs, adverse events.
The efficacy and safety of nivolumab

### Table 1

<table>
<thead>
<tr>
<th>Study</th>
<th>Events</th>
<th>Total</th>
<th>Proportion 95% CI</th>
<th>W (fixed)</th>
<th>W (random)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Study 1</td>
<td>27</td>
<td>135</td>
<td>0.20 (0.14, 0.28)</td>
<td>16.9%</td>
<td>16.9%</td>
</tr>
<tr>
<td>Study 2</td>
<td>9</td>
<td>37</td>
<td>0.24 (0.12, 0.41)</td>
<td>5.3%</td>
<td>5.3%</td>
</tr>
<tr>
<td>Study 3</td>
<td>56</td>
<td>292</td>
<td>0.19 (0.15, 0.24)</td>
<td>35.5%</td>
<td>35.5%</td>
</tr>
<tr>
<td>Study 4</td>
<td>24</td>
<td>111</td>
<td>0.22 (0.14, 0.30)</td>
<td>14.7%</td>
<td>14.7%</td>
</tr>
<tr>
<td>Study 5</td>
<td>6</td>
<td>19</td>
<td>0.32 (0.13, 0.57)</td>
<td>3.2%</td>
<td>3.2%</td>
</tr>
<tr>
<td>Study 6</td>
<td>5</td>
<td>18</td>
<td>0.28 (0.10, 0.53)</td>
<td>2.8%</td>
<td>2.8%</td>
</tr>
<tr>
<td>Study 7</td>
<td>9</td>
<td>37</td>
<td>0.24 (0.12, 0.41)</td>
<td>5.3%</td>
<td>5.3%</td>
</tr>
<tr>
<td>Study 8</td>
<td>24</td>
<td>111</td>
<td>0.22 (0.14, 0.30)</td>
<td>14.7%</td>
<td>14.7%</td>
</tr>
<tr>
<td>Study 9</td>
<td>5</td>
<td>18</td>
<td>0.28 (0.10, 0.53)</td>
<td>2.8%</td>
<td>2.8%</td>
</tr>
<tr>
<td>Study 10</td>
<td>7</td>
<td>51</td>
<td>0.14 (0.06, 0.26)</td>
<td>4.7%</td>
<td>4.7%</td>
</tr>
</tbody>
</table>

#### Fixed effect model

| Study 1                                                               | 817    |       | 0.20 (0.17, 0.23) | 100%      | –          |
| Study 2                                                               | 27     | 135   | 0.20 (0.17, 0.23) | 100%      | –          |

#### Random effects model

| Study 1                                                               | 581    |       | 0.35 (0.22, 0.51) | –         | 100%       |
| Study 2                                                               | 581    |       | 0.47 (0.40, 0.53) | –         | 100%       |

#### Heterogeneity

- Fixed effects model: I²=0.0%, τ²=0.00, P=0.5628
- Random effects model: I²=62.4%, τ²=0.4018, P=0.0001

---

### Figure 2

Summary ORR (A), DCR (B), 1-year OS rate (C), and 1-year PFS rate (D).

**Abbreviations**: ASCO, American Society of Clinical Oncology; WCLC, World Conference of Lung Cancer; CI, confidence interval; DCR, disease control rate; ORR, objective response rate; OS, overall survival; PFS, progression-free survival.

---

### Table 2

<table>
<thead>
<tr>
<th>Study</th>
<th>Events</th>
<th>Total</th>
<th>Proportion 95% CI</th>
<th>W (fixed)</th>
<th>W (random)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Study 1</td>
<td>29</td>
<td>138</td>
<td>0.21 (0.15, 0.29)</td>
<td>24.0%</td>
<td>24.0%</td>
</tr>
<tr>
<td>Study 2</td>
<td>21</td>
<td>37</td>
<td>0.57 (0.39, 0.73)</td>
<td>6.3%</td>
<td>6.3%</td>
</tr>
<tr>
<td>Study 3</td>
<td>149</td>
<td>292</td>
<td>0.51 (0.45, 0.57)</td>
<td>50.9%</td>
<td>50.9%</td>
</tr>
<tr>
<td>Study 4</td>
<td>48</td>
<td>117</td>
<td>0.41 (0.32, 0.50)</td>
<td>19.8%</td>
<td>19.8%</td>
</tr>
<tr>
<td>Study 5</td>
<td>57</td>
<td>135</td>
<td>0.42 (0.35, 0.51)</td>
<td>23.0%</td>
<td>23.0%</td>
</tr>
<tr>
<td>Study 6</td>
<td>130</td>
<td>292</td>
<td>0.45 (0.39, 0.50)</td>
<td>51.2%</td>
<td>51.2%</td>
</tr>
<tr>
<td>Study 7</td>
<td>47</td>
<td>179</td>
<td>0.28 (0.20, 0.33)</td>
<td>24.6%</td>
<td>24.6%</td>
</tr>
<tr>
<td>Study 8</td>
<td>29</td>
<td>51</td>
<td>0.57 (0.42, 0.71)</td>
<td>8.9%</td>
<td>8.9%</td>
</tr>
<tr>
<td>Study 9</td>
<td>24</td>
<td>117</td>
<td>0.41 (0.32, 0.50)</td>
<td>19.8%</td>
<td>19.8%</td>
</tr>
<tr>
<td>Study 10</td>
<td>22</td>
<td>51</td>
<td>0.57 (0.42, 0.71)</td>
<td>8.9%</td>
<td>8.9%</td>
</tr>
</tbody>
</table>

#### Fixed effect model

| Study 1                                                               | 581    |       | 0.47 (0.43, 0.51) | 100%      | –          |
| Study 2                                                               | 581    |       | 0.47 (0.40, 0.53) | 100%      | –          |

#### Random effects model

| Study 1                                                               | 581    |       | 0.47 (0.43, 0.51) | 100%      | –          |
| Study 2                                                               | 581    |       | 0.47 (0.40, 0.53) | 100%      | –          |

#### Heterogeneity

- Fixed effects model: I²=51.3%, τ²=0.0342, P=0.1039
- Random effects model: I²=68.6%, τ²=0.5100, P=0.519

---

### Figure 3

The pooled rate of any grade of AEs of nivolumab (A) and the pooled rate of grade 3–4 AEs of nivolumab (B).

**Abbreviations**: ASCO, American Society of Clinical Oncology; WCLC, World Conference of Lung Cancer; AE, adverse events; CI, confidence interval.
squamous cell lung cancer patients versus non-squamous cell lung cancer patients treated with nivolumab, the odds ratio of ORR was 1.23 (95% CI: 0.63–2.39, \( z=0.61, P=0.54 \)) (Figure 4A). Thereby, the ORR of non-squamous cell lung cancer cohort and squamous cell lung cancer cohort had a resemblance.

**PD-L1 positive versus PD-L1 negative**

In respect of PD-L1 expression level (cut-off value =5%), within the efficacy dose of 3 mg/kg. The pooled ORR of PD-L1 positive lung cancer patients was 31% (95% CI: 24%–38%) with small heterogeneity (\( I^2=40.1\%), \( P=0.188 \)), while the pooled ORR of PD-L1 negative lung cancer patients was 12% (95% CI: 9%–17%). Moreover, for PD-L1 positive patients, the odds ratio of ORR for nivolumab was 3.08 (95% CI: 1.87–5.08, \( z=4.42, P<0.0001 \)), compared to cases with PD-L1 negative tumor (Figure 4B). Therefore, we observed that within the same efficacy dose, greater ORR presented in PD-L1 positive cohort than PD-L1 negative cohort.

**Publication bias**

In regard to the publication bias, Egger’s funnel plot and Egger’s test were performed to assess the publication bias in the literature. The funnel plot and Egger’s funnel plot are presented in (Figure 5A and B), respectively. In addition, all nine eligible studies investigating NSCLC patients yielded a Begg’s test score of \( P=0.3741 \) and an Egger’s test score of \( P=0.3019 \). In general, the absence of publication bias was observed for all nine studies, so all these outcomes reveal that there is no significant publication bias.

**Discussion**

Nivolumab eliminates cancer cells by attaching to the PD-1 ligand on immune cells, while restoring antitumor immune response and having tolerable AEs. Nivolumab exhibited survival improvement in naive melanoma at the very start. Its superior efficacy in melanoma draws enormous attention to investigating the therapeutic effect of nivolumab on NSCLC as well as other tumors. With regard to NSCLC, the efficacy and safety of nivolumab are still under investigation. Although several studies were published, most of them were designed as Phase I or II trials. Although, a series of studies have assessed the efficacy and safety of PD-1 agents, including nivolumab, the efficacy of various doses and safety outcomes of nivolumab were combined, which might lead to huge heterogeneity. So it is important and necessary to merge the data at the same efficacious doses. Therefore,

![Figure 4](https://www.dovepress.com/figure-4-meta-analysis-on-orr-of-squamous-nsclc-versus-non-squamous-nsclc-a-and-meta-analysis-on-orr-of-pd-l1-positive-versus-pd-l1-negative-patients-b.quot;)

**Figure 4** Meta-analysis on ORR of squamous NSCLC versus non-squamous NSCLC (A) and meta-analysis on ORR of PD-L1 positive versus PD-L1 negative patients (B).

**Abbreviations:** CI, confidence interval; NSCLC, non-small-cell lung cancer; ORR, objective response rate; PD-L1, programmed cell death ligand 1.
a meta-analysis merging all available data from correlative studies using the standard dose was warranted to show the real clinical efficacy of nivolumab.

In our study, nivolumab showed durable outcome of ORR with tolerable AEs using the dose of 3 mg/kg in previously treated advanced NSCLC patients. Nevertheless, the ORR of nivolumab was lower than first-line chemotherapy or EGFR tyrosine kinase inhibitors; it was higher than second-line standard docetaxel regimen. The other endpoints (DCR, 1-year-PFS, 1-year-OS) also demonstrated greater efficacy of nivolumab for previously treated advanced NSCLC patients.

Besides, nivolumab revealed manageable toxicities. It was demonstrated that checkpoint inhibitors were associated with a unique series of AEs due to nonspecific immunologic activation. Recent studies have indicated that these AEs are related to the infiltration of highly activated CD4 and CD8 T-cells and increasing production of inflammatory cytokines in otherwise healthy tissues. However, we found that the rate of treatment-related AEs of any grade was 63%, and the grade 3–4 AEs rate was only 8%, which demonstrated that nivolumab is tolerated by these treated patients. The most common treatment-related AEs were fatigue (28%), decreased appetite (13%), nausea (12%), and asthenia (10%). It will be very important for physicians to notice these immune treatment-related AEs and devise proper strategies to manage these problems. As a result, nivolumab is tolerable and regarded as a second-line regimen for previously treated advanced NSCLC patients.

As for subgroup analyses, we demonstrated that using the standard dose of 3 mg/kg, the pooled ORR of squamous NSCLC was similar to non-squamous NSCLC, which reconfirmed clinical efficacy with nivolumab in both squamous and non-squamous NSCLC patients after initial treatment failures. In addition, regardless of the histological types, the efficacy of nivolumab was higher than standard second-line regimen with tolerable AEs. In respect of PD-L1 status (cut-off value =5%), we clarified that the ORR in PD-L1 positive cohort was higher than PD-L1 negative cohort. This finding was in accordance with previous studies. It seems that high-level PD-L1 expression might be a promising response predictor for nivolumab treatment. However, there are several limitations in the study. Most of the included studies were Phase I trials, and there was a lack of sufficient data and sample size to be reliable. Moreover, on the basis of our study, the efficacy and safety of nivolumab combining with other therapy was unknown. Further studies are needed to resolve these limitations.

In conclusion, nivolumab is a promising second-line agent for previously treated advanced NSCLC with manageable AEs. Both squamous and non-squamous NSCLC patients showed similar efficacy. In addition, patients with positive PD-L1 had a higher response rate to nivolumab.

Acknowledgments
No funding was involved. Jiaxing Huang, Yaxiong Zhang, and Jin Sheng share first authorship.

Disclosure
The authors report no conflicts of interest in this work.

References


25. Todd Michael Bauer MMJC. An ongoing phase IIb/IV safety trial of nivolumab (NIVO) in patients (pts) with advanced or metastatic non-small-cell lung cancer (NSCLC) who progressed after receiving 1 or more prior systemic regimens. 2015 ASCO Annual Meeting; 2015.


31. Todd Michael Bauer MMJC. An ongoing phase IIb/IV safety trial of nivolumab (NIVO) in patients (pts) with advanced or metastatic non-small-cell lung cancer (NSCLC) who progressed after receiving 1 or more prior systemic regimens. 2015 ASCO Annual Meeting; 2015.


